نتائج البحث - "Suzette, Girgis"

1

دورية أكاديمية

Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab

المؤلفون: Marie‐Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis

المصدر: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 7, Pp 1117-1129 (2024)

مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2163-8306

URL الوصول: https://doaj.org/article/0dd1551fb54644b2acd2b604cad8206a

View record at Wiley

Find this article in full text from ProQuest

Full Text Finder

2

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

المؤلفون: Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi W. Hilder, Jeffery Russell, Jeffrey Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg

المصدر: Blood Advances. 7:644-648

مصطلحات موضوعية: Hematology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727f72e5fbe7d8308419bbb499db885f
https://doi.org/10.1182/bloodadvances.2022007625

Full Text via ClinicalKey

3

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

المؤلفون: Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis, Yue Guo, Peter Hellemans, Raluca Verona, Natalia Pendás, Qi Xia, Ravit Geva, Emiliano Calvo

المصدر: Investigational New Drugs. 41:93-104

مصطلحات موضوعية: Pharmacology, Oncology, Pharmacology (medical)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b5a4784f928e2b8dfe8c7013fe74699
https://doi.org/10.1007/s10637-022-01319-2

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

4

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

المساهمون: Hematology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life

المصدر: Chari, A, Minnema, M C, Berdeja, J G, Oriol, A, van de Donk, N W C J, Rodríguez-Otero, P, Askari, E, Mateos, M-V, Costa, L J, Caers, J, Verona, R, Girgis, S, Yang, S, Goldsmith, R B, Yao, X, Pillarisetti, K, Hilder, B W, Russell, J, Goldberg, J D & Krishnan, A 2022, ' Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma ', The New England journal of medicine, vol. 387, no. 24, pp. 2232-2244 . https://doi.org/10.1056/NEJMoa2204591
The New England journal of medicine, 387(24), 2232-2244. Massachussetts Medical Society

مصطلحات موضوعية: General Medicine

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8606346460e6e7b33433741bd8ffff5
https://doi.org/10.1056/nejmoa2204591

Find this article in full text from ProQuest

5

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

المؤلفون: Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C Adams, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed

المصدر: Targeted Oncology. 17:433-439

مصطلحات موضوعية: Cancer Research, Oncology, Humans, Administration, Intravenous, Antineoplastic Agents, Pharmacology (medical), B-Cell Maturation Antigen, Multiple Myeloma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f9766eaeac3d6c36a98101ebf36d06
https://doi.org/10.1007/s11523-022-00893-y

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

6

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

المصدر: Blood. 140:241-243

مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ba6f9fa9936194ac18c6a833803e59cc
https://doi.org/10.1182/blood-2022-162709

7

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

المساهمون: Hematology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life

المصدر: The Lancet, 398(10301), 665-674. Elsevier Limited
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname